Current through Register Vol. XLI, No. 38, September 20, 2024
22.1. Each opioid
treatment program shall maintain current quality assurance and quality control
plans that include provisions for:
22.1.a.
Regular and continuous staff education;
22.1.b. An annual review, in consultation
with the advisory council and the peer review committee, of program policies
and procedures; and
22.1.c.
Consideration of ongoing input into program policies and procedures by patients
regarding community concerns;
22.1.d. Development and implementation of
annual patient satisfaction surveys that include a review of patient
satisfaction with operating hours and pricing of services;
22.1.e. Adherence to universal infection
control precautions promulgated by the Center for Disease Control;
22.1.f. An ongoing assessment, measurement
and monitoring of patient outcomes, treatment outcomes and the various
processes including, but not limited to:
22.1.f.1. Reduction or elimination of the
patient's use of illicit opioids, illicit drugs and the problematic use of
licit drugs;
22.1.f.2. Reduction or
elimination of associated criminal activities;
22.1.f.3. Reduction of the patient's
behaviors contributing to the spread of infectious diseases; and
22.1.f.4. Improvement of quality of life
through the restoration of physical and behavioral health and functional
status, including employment or volunteerism, as may be appropriate.
22.2. The opioid
treatment program shall annually collect outcome measurements and results of
patient satisfaction surveys. The governing body and the advisory council shall
review the results and submit the reports to the state authority.
22.3. An opioid treatment program shall
maintain a current "Diversion Control Plan" (DCP) as part of its quality
assurance programs that contains specific measures to reduce the possibility of
diversion of controlled substances from legitimate treatment use. The DCP shall
assign specific responsibility to the medical and administrative staff of the
opioid treatment program for carrying out the diversion control measures and
functions described in the DCP.
22.3.a. The
diversion control plan shall be reviewed and approved by the governing body,
advisory council, peer review council and the state authority.
22.3.b. Diversion control plans shall
minimize the diversion of methadone or other opioid treatment medications to
illicit use. The plan shall include:
22.3.b.1. Clinical and administrative
continuous monitoring of the potential for and actual diversion including an
investigation, tracking and monitoring system of incidents of diversion;
and
22.3.b.2. Proactive planning
and procedures for problem identification, correction and prevention.
